B+
Bull case
25%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
ANGO
AngioDynamicsANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The latest company-reported results showed 8.0% pro forma quarterly revenue growth, 16.7% Med Tech growth, positive adjusted EBITDA, and a Medicare coverage pathway for NanoKnife. Continued adoption could narrow the valuation gap to the packet's $20 analyst median target.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +16.8.
What can break
Execution risk in converting NanoKnife coverage and clinical milestones into procedure volume and revenue.
Momentum
75
Value
42
Sentiment
89
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.00 · Bull $22.00 · Bear $12.50Analysis 2026-09-05; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $20.00
Why
Momentum75 · Δ7d -3.1
Value42 · Δ7d -0.0
Sentiment89 · Δ7d +16.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +16.8.
Contradictions & invalidation
- • Execution risk in converting NanoKnife coverage and clinical milestones into procedure volume and revenue.
- • Low analyst coverage and unavailable target-count data reduce confidence in consensus valuation.
- • ANGO remains loss-making on both GAAP and adjusted measures, Med Device growth was modest, and tariff-related headwinds remain.
Catalyst clock
2026-10-31
Persistent losses and uneven segment momentum
Lead driver: Sentiment · See AI snapshot
Momentum
75
9% active weight
Current posture
7d trendFlat
Δ7d
-3.1
Δ21d
-14.4
Value
42
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.3
Sentiment
89
62% active weight
Current posture
7d trendImproving
Δ7d
+16.8
Δ21d
+11.2
Why this grade
Composite grade A. Momentum 75.1 / Value 41.7 / Sentiment 88.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-05. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$647.68M
Beta
0.52
Shares Out
41.33M
P/E (TTM) · Derived
-17.7
P/S (TTM)
1.81
P/FCF (TTM) · Derived
-212.04
Rev YoY
+8.0%
EPS YoY
+85.3%
Gross Margin
+51.3%
Op Margin
-7.0%
Net Debt
-$42.91M
Current Ratio
2.18
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data